Tackling the complex development landscape of pain medicines
European Pharmaceutical Review
JANUARY 11, 2024
A major limitation is that these drugs generally do not target the specific causes of neuropathic pain, and their efficacy is reduced when the underlying conditions, like nerve damage, cannot be treated effectively. What are the key current challenges in the development of pain medicines? Internet] NIH. cited 2024Jan]. Internet] NIH.
Let's personalize your content